-
|
Business Wire –
8:03 AM ET 05/18/2022
Abiomed (ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock patients during the Society for Cardiovascular Angiography and Interventions 2022 Scientific Sessions, May 19 22, in Atlanta. This press release features multimedia.
|
-
|
Benzinga –
9:54 AM ET 04/28/2022
Abiomed reported its Q4 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Abiomed beat estimated earnings by 6.42%, reporting an EPS of $1.16 versus an estimate of $1.09. Revenue was up $28.60 million from the same period last year.
|
-
|
Reuters –
7:15 AM ET 04/28/2022
ABIOMED Inc (ABMD): * ABIOMED ANNOUNCES FOURTH QUARTER RECORD REVENUE OF $270 MILLION, UP 12% YEAR OVER YEAR. * Q4 NON-GAAP EARNINGS PER SHARE $1.16. * Q4 GAAP EARNINGS PER SHARE $1.31. * Q4 REVENUE ROSE 12 PERCENT TO $270 MILLION. * ANTICIPATES FISCAL YEAR 2023 GLOBAL REVENUE TO BE IN RANGE OF $1.14 BILLION TO $1.18 BILLION. * FY2023 REVENUE VIEW $1.17 BILLION -- REFINITIV IBES DATA.
|
-
|
Business Wire –
7:00 AM ET 04/28/2022
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022.
|
-
|
Benzinga –
4:50 AM ET 04/28/2022
** PBF Energy is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. ** Merck & Co is estimated to report quarterly earnings at $1.83 per share on revenue of $14.68 billion. ** Smith & Nephew is estimated to report earnings for its first quarter. ** Domino's Pizza is estimated to report quarterly earnings at $3.05 per share on revenue of $1.03 billion.
|
-
|
Benzinga –
2:02 PM ET 04/27/2022
Abiomed is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Analysts estimate that Abiomed will report an earnings per share of $1.09. Abiomed bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
|
-
|
Business Wire –
8:02 AM ET 04/26/2022
Abiomed (ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery as part of the heart pumps U.S. Food and Drug Administration Early Feasibility Study. Impella BTR, a forward flow heart pump that is implanted via the axillary artery and sits in the left ventricle, can pump greater than six liters of blood per minute.
|
-
|
Benzinga –
4:20 PM ET 04/19/2022
U.S. indices traded higher Tuesday on continued volatility as traders assess Fed policy outlook, rising Treasury yields and quarterly earnings reports. Here are the day's winners and losers from the S&P 500, according to data from Benzinga Pro. ABIOMED, Inc., Generac Holdings Inc. and Citizens Financial Group Inc were among the top gainers for the SPY.
|
-
|
Business Wire –
7:00 AM ET 04/08/2022
Abiomed, Inc (ABMD). announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial 200-6205; the international number is 526-1599 access code 660077.
|
-
|
Benzinga –
2:04 PM ET 04/06/2022
Abiomed has observed the following analyst ratings within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for Abiomed. Below is a summary of how these 4 analysts rated Abiomed over the past 3 months.
|
-
|
Benzinga –
10:16 AM ET 04/06/2022
According to Morgan Stanley, the prior rating for Royalty Pharma PLC was changed from Equal-Weight to Overweight. According to Keefe, Bruyette & Woods, the prior rating for PJT Partners Inc was changed from Market Perform to Outperform. Guggenheim upgraded the previous rating for Array Technologies Inc from Neutral to Buy.
|
-
|
Business Wire –
8:04 AM ET 04/06/2022
5,000 Patients Treated Globally The versatility and innovation of Abiomeds Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the world. This press release features multimedia.
|
-
|
Business Wire –
7:00 AM ET 03/21/2022
Abiomed, Inc (ABMD). today announced that it will host an investor call on Impella ECP on March 29, 2022 from 4:00 p.m. 5:00 p.m. EDT. A live video webcast of the event will be available March 29 via the link https://events.abiomed.com/ImpellaECP.
|
Page:
|
Today's and Upcoming Events
-
ABMD to announce Q1 earnings (Unconfirmed)
Past Events (last 90 days)
-
ABMD announced Q4 earnings.
Data provided by Thomson Reuters © 2022
|